40,000 patients studied: does a simpler cancer drug dose work just as well?

NCT ID NCT05380336

Completed Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and more cost-effective over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab
What this could lead to: If successful, this study could show that a simpler fixed-dose regimen is just as effective and more cost-efficient than weight-based dosing for metastatic cancer patients.
What could go wrong: This is an observational study using existing health data, not a controlled trial. Results may be influenced by differences between patient groups, and the one-year follow-up may not capture long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer melanoma metastatic malignant neoplasm metastatic melanoma Neoplasm Metastasis non-small cell lung carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER

Contacts and locations

Locations

CHU de Nantes

Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.